“Our company developed from a start-up to a successful public company with over 500 employees and $80 million in annual revenues by following a bold, innovative strategy. This strategy was developed with valuable insight from Atlas Venture, and key to the strategy was a major contract with Glaxo SmithKline, which was facilitated by Atlas' contacts there.”
George Scangos Ph.D., President and CEO
Exelixis

Life Sciences Sector

Life Sciences Portfolio Life Sciences Team

Our life sciences team has been an early investor in over 95 biotechnology companies. We actively manage 32 of these companies today while making new investments in drug discovery and biotechnology.

More than 20 of our investments have gone public, with an aggregate market capitalization in excess of $8 billion, and include companies such as Actelion Pharmaceuticals (SWX: ATLN.ZUR); Alnylam (NASDAQ: ALNY); Anadys (NASDAQ: ANDS); Crucell (NASDAQ: CRXL); deCODE genetics (NASDAQ: DCGN); Exelixis (NASDAQ: EXEL); Momenta (NASDAQ: MNTA); Morphosys (Frankfurt: MOR); Nitromed (NASDAQ: NTMD); NxStage (NASDAQ: NXTM); Renovo (LSE: RNVO) and SGX Pharmaceuticals (NASDAQ: SGXP).

We typically invest in:

  • Product companies with clinical candidates or molecules in the clinic;
  • Drug discovery companies with best in class technologies to accelerate and improve lead generation and optimization, make new targets accessible to drug intervention, shorten the path to the clinic or change the overall cost equation;
  • Select medical device, technology and tool companies.

 
© 2005 Atlas Venture. All rights reserved.